XVIVO partnered with Symic Bio to develop an animation that demonstrates the potential efficacy of their molecule, SB-030.
SB-030 is a novel matrix regulating molecule that alters the pathological response to endothelial injury on the vessel wall.
SB-030 is delivered to the vessel during a vascular procedure and binds to any exposed matrix inhibiting platelet response to any injury.
Because SB-030 is bound to the site of damage, platelets no longer recognize the injury and do not bind or become activated. This allows healing with reduced complications.
To view a related animation click here: Voxelotor An Investigational Drug for Sickle Cell Disease.